← Back to Search

Serotonin Norepinephrine Reuptake Inhibitor

Male for Healthy Subjects (DVS Trial)

Phase 1
Waitlist Available
Led By Pierre Blier, M.D., Ph.D.
Research Sponsored by University of Ottawa
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 month
Awards & highlights

DVS Trial Summary

DVS is the main metabolite of the antidepressant/anxiolytic medication Venlafaxine (Effexor). Like parent compound, DVS is an antidepressant inhibiting both serotonin (5-HT) and norepinephrine (NE) reuptake. However, no studies to date describe the in vivo potency of this drug on monoamines reuptake. Consequently, it appears essential to determine the potency of DVS in human subjects using a wide dose range in order to determine at which dose(s) it starts inhibiting 5-HT and NE reuptake. The investigators are interested in learning whether there is a gender difference in the dose of the study medication at which NE reuptake inhibition occurs.

DVS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 month
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 month for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The degree of norepinephrine reuptake in response to the increasing levels of the study medication will be assessed and compared between genders
Secondary outcome measures
The degree of serotonin reuptake in response to the increasing levels of the study medication will be assessed and compared between genders

Side effects data

From 2015 Phase 4 trial • 53 Patients • NCT01916824
21%
Headache
17%
Insomnia
13%
Upper Respiratory Tract Infection
8%
Diarrhea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Participants With Major Depressive Disorder
Healthy Controls

DVS Trial Design

2Treatment groups
Experimental Treatment
Group I: MaleExperimental Treatment1 Intervention
Group II: FemaleExperimental Treatment1 Intervention

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of OttawaLead Sponsor
208 Previous Clinical Trials
267,136 Total Patients Enrolled
Pierre Blier, M.D., Ph.D.Principal InvestigatorUniversity of Ottawa

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate in Healthy Volunteers
2010. "Effectiveness of the Dual Serotonin Norepinephrine Reuptake Inhibitor Desvenlafaxine Succinate in Healthy Volunteers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01101152.
All > Health
~1 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top